Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | AHCY | P23526 | 1/20 | 0.33 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.32 |
| ▸ | ADK | P55263 | 5/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23191952 | 1.00 | GBA1 (0.39) | GBA1AHCYCD209ADKSLC2A1 | |
| SCHEMBL18517492 | 0.83 | GBA1 (0.38) | GBA1AHCYCD209ADKLGALS8 | |
| SCHEMBL17179645 | 0.83 | GBA1 (0.38) | GBA1AHCYCD209ADKLGALS8 | |
| SCHEMBL24411660 | 0.81 | GBA1 (0.47) | GBA1AHCYCD209ADK | |
| SCHEMBL18126572 | 0.81 | GBA1 (0.47) | GBA1AHCYCD209ADK | |
| SCHEMBL15121344 | 0.81 | GBA1 (0.47) | GBA1AHCYCD209ADK | |
| SCHEMBL24265196 | 0.81 | GBA1 (0.47) | GBA1AHCYCD209ADK | |
| SCHEMBL24265201 | 0.81 | GBA1 (0.47) | GBA1AHCYCD209ADK | |
| SCHEMBL16284119 | 0.81 | GBA1 (0.47) | GBA1AHCYCD209ADK | |
| SCHEMBL24265199 | 0.81 | GBA1 (0.47) | GBA1AHCYCD209ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | GBA1 117/4885AHCY 3320/4885CD209 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.